EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nano-Polymers as Cas9 Inhibitors

Oksana Chepurna, Avradip Chatterjee iD, Yuanqing Li, Hong Ding iD, Ramachandran Murali iD, Keith L Black, Tao Sun

Polymers · 05.02.2025 · 17 (3) · 417

DOI: 10.3390/polym17030417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Polymers, online erschienen am 05.02.2025. Verfasst von Oksana Chepurna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCLA Clinical and Translational Science Institute (UCLA CTSI) Core Voucher.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite wide applications of CRISPR/Cas9 technology, effective approaches for CRISPR delivery with functional control are limited. In an attempt to develop a nanoscale CRSIPR/Cas9 delivery platform, we discovered that several biocompatible polymers, including polymalic acid (PMLA), polyglutamic acid (PGA), and polyaspartic acid (PLD), when conjugated with a trileucine (LLL) moiety, can effectively inhibit Cas9 nuclease function. The Cas9 inhibition by those polymers is dose-dependent, with varying efficiency to achieve 100% inhibition. Further biophysical studies revealed that PMLA-LLL directly binds the Cas9 protein, resulting in a substantial decrease in Cas9/sgRNA binding affinity. Transmission electron microscopy and molecular docking were performed to provide a possible binding mechanism for PMLA-LLL to interact with Cas9. This work identified a new class of Cas9 inhibitor in nano-polymer form. These biodegradable polymers may serve as novel Cas9 delivery vehicles with a potential to enhance the precision of Cas9-mediated gene editing.

Schlagwörter

Stichwörter der Autor:innen

CRISPR/Cas9inhibitornano-polymerpolyaspartic acidpolyglutamic acidpolymalic acidtrileucine

Autor:innen und Institutionen

  • Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Department of Biomedical Sciences, Research Division of Immunology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Shanghai Institute of Material Medica, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, Shanghai 200231, China.
  • School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.

ORCID-Profile: Avradip Chatterjee, Hong Ding, Ramachandran Murali

Förderung

  • UCLA Clinical and Translational Science Institute (UCLA CTSI) Core Voucher

Zitieren

APA

Chepurna, O., Chatterjee, A., Li, Y., Ding, H., Murali, R., Black, K. L., & Sun, T. (2025). Nano-Polymers as Cas9 Inhibitors. Polymers, 17(3), 417. https://doi.org/10.3390/polym17030417

Vancouver

Chepurna O, Chatterjee A, Li Y, Ding H, Murali R, Black KL, et al. Nano-Polymers as Cas9 Inhibitors. Polymers. 2025;17(3):417. doi:10.3390/polym17030417

BibTeX
@article{Chepurna2025,
  author = {Chepurna, Oksana and Chatterjee, Avradip and Li, Yuanqing and Ding, Hong and Murali, Ramachandran and Black, Keith L and Sun, Tao},
  title = {Nano-Polymers as Cas9 Inhibitors},
  journal = {Polymers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {417},
  doi = {10.3390/polym17030417}
}
Kostenlos starten →